Press Release

Increasing Prevalence of Cancer Cases Expected to Spur the Growth of the Global DNA Methylation Market

The Global DNA Methylation market is growing at a high rate on account of increasing prevalence of global cancer cases and burgeoning healthcare expenditure toward infrastructural development. Moreover, rising number of approvals by the government agencies for the launch of innovative products, surging degree of government funding in the developed and developing countries on research activities, and escalating use of early-stage biomarkers in cancer profiling are the factors projected to proliferate the growth of DNA methylation in the forecast period.

According to MarkNtel Advisors’ research report “Global DNA Methylation Market Analysis, 2020”, the Global DNA Methylation market is anticipated to grow at a considerable CAGR during 2020-25. Based on Technology, Polymerase Chain Reaction (PCR) acquired the significant market share in 2019. PCR is used to detect changes in DNA methylation with a focus on cancer diagnosis. The PCR technology is used to rapidly make millions to billions of copies of a specific DNA sample in number of medical laboratory research programs and clinical techniques for detection of bacteria or viruses (particularly AIDS), biomedical research, and diagnosis of genetic disorders.

“Global DNA Methylation Market Analysis, 2020” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and growth opportunities available for DNA Methylation providers across the globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.      

North America Acquired the Highest Market Share

Based on Region, North America acquired the highest market share in 2019. US acquired the majority market share in the North America segment owing to the factors such as burgeoning incidences of Colorectal cancer (CRC) cases, rising funding by the governments in research activities, and ageing population that can lead to individuals developing cancer due to changes in DNA Methylation. Colorectal cancer is among second leading cause of cancer deaths among men and women in the United States. Thus, this is anticipated to bolster the growth of the DNA Methylation Market in the forthcoming period as stated in MarkNtel Advisors’ research report “Global DNA Methylation Market Analysis, 2020”. 

According to MarkNtel Advisors, the key players with a considerable market share in the Global DNA Methylation market are Abcam PLC, Active Motif, Inc, Agilent Technologies, Inc, Bio-Rad Laboratories, Inc., Diagenode Diagnostics S.A., EpiGentek Group Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., Merck KGaA, New England Biolabs, Inc., Pacific Biosciences of California, Inc., PerkinElmer, Inc., Thermo Fisher Scientific Inc., and Zymo Research Corporation etc.

Market Segmentation:

1. By Product Type (Consumables, Instruments, Software)
2. By Technology (Polymerase Chain Reaction (PCR), Sequencing [ Next-Generation Sequencing (NGS), Traditional Sequencing], Microarray, Others)
3. By Application (Clinical Applications, Translational Research [Oncology Research, Non-Oncology Research, Other Research Applications])
4. By End-User (Pharmaceutical and Biotechnology Companies, Research and Academic Institutions, Contract Research Organizations, Other)
5. By Region (North America, South America, Europe, Asia-Pacific, Middle East & Africa)
6. By Country (US, Canada, Brazil, Argentina, Spain, UK, Germany, France, Italy, China, India, Japan, South Korea, Australia, Israel, South Africa),
7. By Company (Abcam PLC, Active Motif, Inc, Agilent Technologies, Inc, Bio-Rad Laboratories, Inc., Diagenode Diagnostics S.A., EpiGentek Group Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., Merck KGaA, New England Biolabs, Inc., Pacific Biosciences of California, Inc., PerkinElmer, Inc., Thermo Fisher Scientific Inc., Zymo Research Corporation etc.)

Key questions answered in the study:

1. What are the current and future trends of the DNA Methylation industry?
2. How the industry has been evolving in terms of end-user demand and application areas?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the DNA Methylation industry?
5. What is the customer orientation, purchase behavior, and expectations from the DNA Methylation firms across various regions?